CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals completed a private placement financing on May 5, 2026, raising gross proceeds of approximately $22.5 million, which alleviates prior substantial doubt about its ability to continue as a going concern. The company also announced a new corporate strategy focused on developing innovative therapies for serious diseases and made significant changes to its executive leadership team. For the first quarter of 2026, CNS Pharmaceuticals reported a net loss of $4.94 million, with cash and cash equivalents totaling $2.95 million as of March 31, 2026.

CNS Pharmaceuticals, Inc. announced a private placement with institutional investors, raising approximately $22.5 million in gross proceeds. The offering included 650,000 shares of common stock at $2.30 per share and 9,143,479 pre-funded warrants at $2.299 per warrant. The company intends to use the net proceeds to identify, acquire, and advance new assets, as well as for working capital and general corporate purposes. Additionally, Jerzy (George) Gumulka resigned from the Board of Directors, and Michal Fisher was appointed as an independent director.

CNS Pharmaceuticals, Inc. filed an Amendment No. 1 to its 10-K to include Part III information, which was omitted from the original filing. This amendment details significant changes in the executive leadership team, including the appointment of a new CEO, CFO, CMO, and CTO in early 2026. It also provides information on the departure of the former CEO and compensation details for both former and newly appointed executives.